Sirtuin 1 in Endothelial Dysfunction and Cardiovascular Aging

Stefano Ministrini 1,2, Yustina M. Puspitasari 1, Georgia Beer 1, Luca Liberale 1,3, Fabrizio Montecucco 3,4 and Giovanni G. Camici 1,5,6*

1 Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland, 2 Internal Medicine, Angiology and Atherosclerosis, Department of Medicine and Surgery, University of Perugia, Perugia, Italy, 3 First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy, 4 Istituto di Ricerca e Cura a Carattere Scientifico Ospedale Policlinico San Martino Genoa–Italian Cardiovascular Network, Genoa, Italy, 5 Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland, 6 Department of Research and Education, University Hospital Zurich, Zurich, Switzerland

Sirtuin 1 (SIRT1) is a histone deacetylase belonging to the family of Sirtuins, a class of nicotinamide adenine dinucleotide (NAD+)-dependent enzymes with multiple metabolic functions. SIRT1 localizes in the nucleus and cytoplasm, and is implicated in the regulation of cell survival in response to several stimuli, including metabolic ones. The expression of SIRT1 is associated with lifespan and is reduced with aging both in animal models and in humans, where the lack of SIRT1 is regarded as a potential mediator of age-related cardiovascular diseases. In this review, we will summarize the extensive evidence linking SIRT1 functional and quantitative defects to cellular senescence and aging, with particular regard to their role in determining endothelial dysfunction and consequent cardiovascular diseases. Ultimately, we outline the translational perspectives for this topic, in order to highlight the missing evidence and the future research steps.

Keywords: sirtuin (SIRT1), aging–old age–seniors, eNOS (endothelial nitric oxide synthase), inflammaging, endothelial (dys)function, atherosclerosis, cardiovascular disease

INTRODUCTION

Aging is defined as the result of a progressive functional decay in multiple tissues and physiologic functions. Cellular senescence, defined as a permanent arrest of the cell cycle, and the subsequent progression toward apoptosis, is one of the cellular mechanisms contributing to the loss of tissue regenerative potential and progressive loss of function with aging (Hernandez-Segura et al., 2018).

Overall, aging is associated with an increased risk of diseases and death, with different organs and systems being differently influenced by aging, and whereby the cardiovascular system is among the most severely hit. As a result, age represents the most relevant risk factor for cardiovascular and cerebrovascular diseases (Camici et al., 2015). Accordingly, the possibility to address the molecular mechanisms underlying aging of the cardiovascular system is an exciting perspective in order to reduce the burden of death and disability associated with cardiovascular diseases.

The interest in Sirtuins emerged as pioneering studies demonstrated an increased lifespan of yeast Saccharomyces cerevisiae with Sir2 (Silent information regulator 2) overexpression, whereas a loss of function of Sir2 leads to defect in epigenetic silencing, DNA repair process, and shorter lifespan (Kaehlerlein et al., 1999). Such effect was then demonstrated in animals, Caenorhabditis elegans and Drosophila, showing the highly conserved roles and domains of Sir2 (Tissenbaum and Guarente, 2001; Rogina and Helfand, 2004; Viswanathan et al., 2005). Mammals express seven homologs of Sir2, named Sirtuins (i.e., SIRT1–SIRT7) (Yamamoto et al., 2007). Sirtuins are located in different cellular compartments and exert their role by acting on different targets, in a
non-redundant manner (Liberale et al., 2020a; Puspitasari et al., 2021). To date, Sirtuin 1 (SIRT1), localized in the nucleus, is the most well-studied and the best characterized of mammalian sirtuins.

This narrative review is based on the material available on PubMed as of June 2021. The following search terms were employed: “Sirtuins; SIRT1” in combination with “endothelial (dys)function; cardiovascular disease.”

In the following paragraphs we will summarize the existing evidence about the pathophysiological role of SIRT1 in atherosclerotic cardiovascular disease (ASCVD), and in particular in one of its main functional features, namely endothelial dysfunction (ED).

A PARADIGM FOR CARDIOVASCULAR AGING: THE ROLE OF SIRTUINS

Sirtuins are a family of nicotinamide adenine dinucleotide (NAD+)-dependent enzymes that catalyze histone and non-histone deacetylation of lysine residues (Guarente, 2011; Camici et al., 2015; Winnik et al., 2015). Sirtuins belong to class III histone deacetylases, and their catalytic activity is regulated by the dynamic changes of NAD+ level and NAD+/NADH ratio (Grabowska et al., 2017). Due to their dependency on NAD+ as co-substrate, sirtuins have been implicated in various cellular processes, including modulation of cellular redox state and mediation of heterochromatin formation (Dang, 2014; Singh et al., 2018). Multiple studies demonstrated the involvement of sirtuins in glucose and lipid metabolism, suggesting their role in maintaining metabolic health (Houtkooper et al., 2012).

SIRT1 is the closest mammalian homolog of the yeast Sir2 protein (Michan and Sinclair, 2007). SIRT1 was demonstrated to participate in various biological processes, including DNA repair, inflammation, autophagy, and longevity. Thus, its function was associated to several diseases, including ASCVD (Haigis and Guarente, 2006; Chen et al., 2020). A large number of proteins were identified as substrates of SIRT1. The first recognized function of SIRT1 is deacetylation of lysine residues of histone protein H1, H3, and H4, thus modulating chromatin structure and expression of target genes (Singh et al., 2018; Chen et al., 2020). Besides, non-histone proteins were recognized as its targets, including p53, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and the forkhead box O class (FOXO) transcription factors.

To date, the association of SIRT1 with aging and longevity has been described in human and non-human mammals. Specifically, aging is associated with a significant decrease of SIRT1 activity and expression in several organs and tissue, including the cardiovascular system (Braidy et al., 2011; Donato et al., 2011). This phenomenon is partially driven by the decline in NAD+ levels observed with aging, yet experimental evidence demonstrated that SIRT1 inhibition leads to genomic instability and development of a senescent phenotype in endothelial cells, irrespective of NAD+ bio-availability (Mostoslavsky et al., 2006; Ota et al., 2007).

Senescence of endothelial cells is the result of several mechanisms, such as DNA injury, telomeres shortening below the critical length of 50–200 base pairs, mitochondrial dysfunction with accumulation of reactive oxygen species (ROS), and impaired proteostasis, following a failure of lysosomal protein degradation through autophagy or the ubiquitin-proteasome system (Laina et al., 2018).

Sirtuins have been reported to participate in DNA single-chain and double chain damage repair by deacetylating the DNA repair machinery components (Yamamori et al., 2009; Alves-Fernandes and Jasiulionis, 2019; Lagunas-Rangel, 2019) and p53, a crucial process for cell recovery after DNA injury (Yamamori et al., 2009). Furthermore, SIRT1 promotes the elongation of telomeres (Palacios et al., 2010) through the induction of the telomere reverse transcriptase (TERT), mediated by c-Myc activation (De Bonis et al., 2014).

SIRT1 indirectly modulates mitochondrial ROS production and promotes the expression of antioxidants through the induction of the FOXO transcription factors (Maiese, 2021). Sources of ROS include mitochondrial respiration, catabolism of purine bases through xanthine oxidase, cyclooxygenases, and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (Panth et al., 2016). These processes are ubiquitous in mammals’ tissues and, therefore, the redox balance is maintained in a steady state by endogenous anti-oxidant systems (Wu et al., 2004; Panth et al., 2016; Bacchetti et al., 2020). SIRT1 plays an active role in the cellular defense against oxidative stress and, at the same time, its function is affected by the presence of ROS through post-translational modifications (Hwang et al., 2013).

FOXO transcription factors are also involved in inflammation and autophagy, together with the mechanistic target of rapamycin (mTOR) (Singh et al., 2018; Cheng, 2019; Chen et al., 2020). The latter is a negative regulator of autophagy and impaired autophagy associates to accumulation of oxidative damage, loss of proteostasis, genomic instability and epigenetic alteration, inducing cellular senescence (Rajendran et al., 2019; Stead et al., 2019). Senescent cells, although quiescent under a replicative point of view, are metabolically active and develop a peculiar senescence associated secretory profile (SASP), consisting in molecules with prevalent pro-inflammatory effects (Cayo et al., 2021). Activation of mTOR was associated with both a reduction and an enhancement of autophagy and, consequently, with both a promotion and a prevention of senescence (Laberge et al., 2015; Sung et al., 2018). As proposed by Cayo et al. the effect of mTOR on autophagy probably depends on the cellular senescence status (Cayo et al., 2021). Takeda-Watanabe and coll. found that SIRT1 inhibition results in increased phosphorylation of mTOR and its downstream target, p70-s6 kinase, with a net decrease in autophagy and increase in inflammation in macrophages (Takeda-Watanabe et al., 2012).

Inflammation has a relevant impact on endothelial dysfunction and aging; this notion was recently reinforced with the coining of the new term “inflamm-aging” (Liberale et al., 2020b). In this context, oxidative stress plays a pivotal role in the development of inflamming through the activation of different intracellular pathways converging on the transcription factor NF-κB (Morgan and Liu, 2011) and leading to the release
of pro-inflammatory cytokines and pro-thrombotic factors. SIRT1 interacts with NF-κB through the RelA/p65 subunit and deacetylates it at Lys310, leading to inhibition of signaling and suppression of inflammation (Yeung et al., 2004). Conversely, NF-κB down-regulates SIRT1 activity through the expression of miR-34a, interferon γ (IFNγ), and ROS (Kauppinen et al., 2013).

Endothelial dysfunction (ED) is a main feature of cardiovascular aging. It is defined as the failure of endothelium to mediate an adequate vasodilatory response to hypoxia or hemodynamic stimuli, such as shear stress (Lüscher and Corti, 2004; Godo and Shimokawa, 2017). ED is associated with a pro-inflammatory and pro-thrombotic status, and eventually with an increased risk of cardiovascular events (Bonetti et al., 2004; Kitta et al., 2009).

Endothelial cells exert their functions through multiple, redundant, molecular pathways, the most relevant being nitric oxide (NO) production. ED is characterized by a reduced NO bioavailability, to such an extent that this itself is also considered as a definition for ED (Dimitris et al., 2011). NO is a soluble radical with vasodilatorial, anti-inflammatory, anti-adhesive and anti-thrombotic properties, produced by the oxidation of L-arginine to L-citrulline, catalyzed by the enzyme nitric oxide synthase (NOS) (Cyr et al., 2020). Endothelial cells are characterized by a constitutively expressed isoform of NOS, named endothelial NOS (eNOS), whereas many other cell types can express the inducible isoform of NOS (iNOS) under cytokines stimulation ( Förstermann and Sessa, 2012).

The imbalance between substrate availability and NO production by eNOS is termed eNOS uncoupling and is a pivotal mechanism of endothelial dysfunction. The main cause of eNOS uncoupling is the unbalance of the redox state toward oxidation, caused by ROS (Yoshida and Kisugi, 2010; Bacchetti et al., 2020). Other causes of eNOS uncoupling include asymmetric dimethyl-L-arginine (ADMA) (Susanne et al., 2014) and enzymatic post-translational modifications of eNOS (Fleming and Busse, 2003; Chen et al., 2010). Finally, the bioavailability of L-arginine itself can be reduced by the activity of arginases, produced by endothelial and inflammatory cells (Berkowitz et al., 2003).

SIRT1 promotes NO availability through different direct and indirect mechanisms. Most importantly, SIRT1 has a direct activating effect on eNOS through deacetylation at Lys496 and Lys506 (Mattagajasingh et al., 2007). Interestingly, a positive feedback between NO and SIRT1 exists, since NO promotes in turn the transcription of SIRT1 (Arunachalam et al., 2010; Caito et al., 2010). Additionally, SIRT1 inhibits the transcription of the adapter protein p66Shc through deacetylation of the histone protein H3 in the promoter region. Since p66Shc promotes the mitochondrial formation of ROS and inhibits the transcription of the antioxidant enzyme superoxide dismutase 2 (SOD2), its downregulation results in a net antioxidant effect (Di Lisa et al., 2009; Trinei et al., 2013). Finally, SIRT1 was reported to induce the nuclear factor erythroid 2-related factor 2 (Nrf2), a transcription factor having a key role in the expression of the most relevant anti-oxidant enzymes, such as glutathione S-transferase Ya (GST Ya) subunit, heme oxygenase 1 (HO-1), and γ-glutamylcysteine synthetase (γ-GCS) (Kaspar et al., 2009; Kawai et al., 2011; Ma et al., 2019).

By regulating the balance between oxidant and anti-oxidant systems, SIRT1 holds specific functions at the level of the endothelium and arterial wall. The main physiologic effects of SIRT1 in the endothelium are summarized in Figure 1. More in general, SIRT1 preserves endothelial function and integrity from the detrimental effects of oxidative stress. Indeed, oxidative stress induces premature cell senescence and apoptosis in endothelial cells through the acetylation of FOXO3 and p53, whereas SIRT1 promotes their deacetylation and, eventually, cell survival (Brunet et al., 1999, 2004; Ota et al., 2007, 2008). Noteworthy, the acetylation of FOXO3, induced by oxidative stress, is able to promote also ROS detoxification and DNA repair (Kops et al., 2002; Tran et al., 2002); so, it is expected to have a dual effect on endothelial cells survival. Interestingly, the deacetylating effect of SIRT1 on FOXO3 does not affect its ability to arrest the cell cycle and provide ROS detoxification and DNA repair (Brunet et al., 2004). Furthermore, FOXO3 regulates multiple functions of vascular smooth muscle cells (VSMCs), including migration, differentiation, proliferation, contractility and senescence (Allard et al., 2008; Huang et al., 2015; Jin et al., 2015; Wang et al., 2015; Liu et al., 2018). In particular, the SIRT1/FOXO3 axis has been demonstrated to promote differentiation and contractility of VSMCs (Huang et al., 2015; Liu et al., 2018), and these novel mechanisms could contribute to the overall effect of SIRT1 on vascular function.

Finally, oxidative stress promotes endothelial-to-mesenchymal transition, a pivotal process in neoangiogenesis and vascular development, but associated with cardiovascular diseases and ED, too (Kovacic et al., 2019).

Chronic low-grade systemic inflammation was identified as a main feature at the crossroad of aging, atherosclerosis and ED (Steyers and Miller, 2014; Ministri et al., 2021). Pro-inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin 1 (IL-1) and IFN-γ, have a detrimental effect on endothelial function, promoting the apoptosis of endothelial cells and impairing the bioavailability of NO through multiple mechanisms, such as inhibition of eNOS gene expression, degradation of eNOS mRNA, inhibition of ADMA degradation and promotion of ROS production by NADPH oxidase (Carbone and Montecucco, 2015). As reported above, SIRT1 interferes with the signaling of these pro-inflammatory molecules, through inhibition of NF-κB and promotion of the immune-modulatory FOXO transcription factors (Peng, 2008), thus exerting an overall anti-inflammatory effect and blunting the age-related ED.

SIRT1 IN CARDIOVASCULAR DISEASES

As a ubiquitous molecule with a role in multiple cell functions, the relationship between SIRT1 and cardiovascular disease is not limited to endothelial function. In particular, SIRT1 counteracts the progression of atherosclerotic lesions through different actions (Zhang et al., 2008), including oxidation of lipoproteins (Stein et al., 2010), sub-endothelial inflammatory cells infiltration (Breitenstein et al., 2013), senescence of endothelial progenitor...
SIRT1 and endothelial dysfunction. Summary of molecular mechanisms (created with BioRender.com). ADMA, asymmetric dimethyl-arginine; APE1, apurinic/apyrimidinic endonuclease 1; eNOS, endothelial nitric oxide synthase; FOXO, forkhead box O class; γ-GCS, γ-glutamylcysteine synthetase; GST Ya, glutathione S-transferase Ya; HO 1, heme oxygenase 1; IFNγ, interferon γ; mTOR, mechanistic target of Rapamycin; NAD: nicotinamide adenine dinucleotide; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Nrf2, nuclear factor erythroid 2—related factor 2; ROS, reactive oxygen species; SIRT1, Sirtuin 1; SOD2, superoxide dismutase 2.

cells (Ming et al., 2016), neo-intima proliferation (Li et al., 2011) and plaque destabilization (Xia et al., 2012).

Furthermore, SIRT1 has a glucose lowering action, since it promotes insulin secretion and the peripheral utilization of glucose (Strycharz et al., 2018). As it is well-known, hyperglycemia, insulin resistance and diabetes mellitus are major determinants of cardiovascular diseases, and the glucose-lowering property of SIRT1 is thought to contribute to its protective function toward cardiovascular diseases.

Moreover, SIRT1 holds important roles also in cardiomyocytes, where it exerts anti-apoptotic functions (Matsushima and Sadoshima, 2015), counteracts endoplasmic reticulum stress (Prola et al., 2017), increases myocardial contractility (Hsu et al., 2017) and resistance to ischemia/reperfusion injury (Wang et al., 2018). SIRT1 is upregulated during pressure overload, caloric restriction and physical exercise, whereas it is downregulated during acute ischemia (Matsushima and Sadoshima, 2015; Najafipour et al., 2021). Interestingly, also constitutional overexpression of SIRT1 in transgenic mice was associated with a reduced contractile function of the myocardium (Alcendor et al., 2007; Kawashima et al., 2011) and, therefore, a U-shaped dose-response curve was hypothesized for the relationship between SIRT1 and myocardial function.

Considering the above, SIRT1 is expected to have a relevant effect on the burden of ASCVD in humans. Consistently, a reduced intracellular expression of SIRT1 gene was observed in patients with stable coronary artery disease (sCAD) and acute coronary syndrome (Breitenstein et al., 2013; Hu et al., 2015), whereas increased circulating levels were associated with sCAD (Kilic et al., 2014). Conversely, lower levels of circulating SIRT1 were associated with a history of atrial fibrillation (Kalstad et al., 2021), whereas an increased levels were observed in the left atrial appendage of patients with valvular atrial fibrillation (Sun et al., 2012).

These apparent discrepancies can be explained considering the multiple epigenetic factors differently regulating the expression of SIRT1 in the various cell types.
More robust evidence for the association between SIRT1 and the ASCVD in humans was collected in genomic studies. Multiple single nucleotide polymorphisms (SNPs) of the SIRT1 gene have been found to associate with ASCVD: the polymorphisms rs7069102 C>G, localized in the intron 4, and rs2273773 C>T, localized in the exon 5, are associated with an increased risk of sCAD, an increased level of circulating SIRT1 and a reduced expression of eNOS (Kilic et al., 2014). The polymorphism rs12413112 A>G, localized in the 3’ untranscribed region, was negatively associated with the presence of CAD (Nasiri et al., 2018), but positively with the presence of carotid intima-media thickness (cIMT) (Kedenko et al., 2014). Conversely, the intronic polymorphism rs1467568 A>G has been associated with a reduced cIMT (Kedenko et al., 2014), but only in the male sex, and with a borderline significant reduction for the risk of CAD (Nasiri et al., 2018). Ultimately, the polymorphism rs3758391 T>C located in the gene promoter is associated with a higher expression of SIRT1 mRNA during acute coronary syndromes (Hu et al., 2015).

**TRANSLATIONAL RELEVANCE OF SIRT1: WHERE DO WE STAND SO FAR?**

Considering the above-mentioned evidence, the possibility to enhance the activity of SIRT1 through pharmacologic and non-pharmacologic treatments for the management or prevention of age-associated diseases, has become increasingly appealing. The main therapeutic strategies, and the relative claimed mechanisms of action, are summarized in **Figure 2**.

Caloric restriction (CR) is the most consistent non-pharmacologic intervention to increase lifespan in animal models (Canto and Auwerx, 2009). It is defined as a moderate reduction of caloric intake (usually 20–49%), compared to a normal ad libitum diet, without compromising the intake of essential macro- and micronutrients (Piper and Bartke, 2008). CR was associated with an increased expression of SIRT1 both in animal models and humans (Guarente, 2013), and SIRT1 was suggested as the main mediator of prolonged lifespan after CR since the genetic deletion of SIRT1 reduces the benefits of CR in
murine models (Chen et al., 2005). Reciprocally, both high fat diet and obesity lead to a reduced expression of SIRT1 in both animals and humans (Guarente, 2013). Multiple hypotheses were proposed to explain the link between CR, SIRT1, and prolonged lifespan, all involving the bioavailability of NAD+ as limiting factor for the activity of SIRT1 (Cantó and Auwerx, 2009), but none of these hypotheses found an experimental confirmation. Currently, it is widespread opinion that CR leads to lifespan prolongation through multiple biochemical pathways, both Sirtuins-dependent and -independent (Lee et al., 2019).

CR activates eNOS and increases the bioavailability of NO, leading to an improvement of endothelial function in animals and humans (Zanetti et al., 2010; Shinmura, 2011). Overall, CR showed a positive effect on cardiovascular aging and atherosclerosis, both in animals and humans, through multiple mechanisms, including the amelioration of systemic inflammation, ROS production, dyslipidemia, hypertension, and insulin resistance (Abiri and Vafa, 2019). However, to date we are unable to discriminate whether these effects are mediated by SIRT1 and to which extent. Interestingly, it was suggested that some nutritional treatments like intermittent fasting could mimic the effect of CR in humans producing an analog effect on SIRT1 activity (Abiri and Vafa, 2019).

Physical activity (PA) has an established role in cardiovascular prevention, because of its beneficial effects on insulin sensitivity, lipid profile, blood pressure, and cardiorespiratory fitness (Myers et al., 2019). PA was associated with an increased expression of SIRT1 and a reduction of ROS in the skeletal muscle, both in animals and in humans (Pacifici et al., 2019). This effect was observed also in older animals, suggesting that PA could at least partially revert the age-related decay of SIRT1 activity (Ferrara et al., 2008). However, the extent of SIRT1 activation seems to be age-dependent, with a reducing enhancement with advancing age (Huang et al., 2016). Interestingly, PA-induced increased SIRT1 was also observed in animal models of myocardial infarction, and was associated with a reduction of apoptotic markers and overall myocardial damage (Donniacuo et al., 2019), suggesting that SIRT1 could play a role in mediating the beneficial effects of PA after ischemic myocardial damage.

Pharmacologic modulation of SIRT1 activity is also a promising opportunity. Two main classes of substances were observed to enhance SIRT1 activity: natural polyphenolic substances, such as Resveratrol, Fisetin and Quercetin, and synthetic small molecules, such as SRT1720, SRT1460, Selisistat (EX 527), SCIC2.1 and AGK2 (Bai et al., 2018; Scisciola et al., 2020).

Resveratrol has recently gained attention because of its anti-oxidant properties, and several potential health benefits of resveratrol were accordingly proposed. Resveratrol is a natural-derived flavonoid, with several direct and indirect molecular targets, including SIRT1 (Hori et al., 2013; Liberale et al., 2019; Li et al., 2019). Notably, Resveratrol is a non-specific activator of Sirtuins and some of the observed effects could be mediated also by Sirtuins other than SIRT1 (Sun et al., 2021). Resveratrol directly induces the transcription of SIRT1 (Xia et al., 2017), increases the bioavailability of NAD+ through the inhibition of phosphodiesterases (Park et al., 2012) and promotes the binding of SIRT1 to its nuclear activator lamin A (Liu et al., 2012). Interestingly, a mutation of lamin A gene (LMNA) causes, in humans, Hutchinson-Gilford progeria syndrome, characterized by premature death due to cardiovascular diseases (Ahmed et al., 2018). Resveratrol was demonstrated to increase the expression of eNOS in vitro, in a SIRT1/FOXO dependent manner (Xia et al., 2013). Moreover, Resveratrol enhances the activity of eNOS, promoting the phosphorylation at Ser-1177 by adenosine-mononucleotide-activated protein kinase (AMPK) (Xu et al., 2009; Heiss and Dirsch, 2014) and the deacetylation at Lys496 and Lys506 by SIRT1 (Mattagajasingh et al., 2007; Arunachalam et al., 2010). Oral administration of resveratrol was demonstrated to improve endothelial function in different animal models of cardiometabolic diseases, such as systemic hypertension (Dolinsky et al., 2013), diabetes mellitus (Zhang et al., 2009) and dyslipidemia (Zou et al., 2003). However, a large meta-analysis did not find any significant difference between subjects treated with Resveratrol and controls in terms of plasma glucose, cholesterol, and blood pressure (Sahebkar et al., 2015). The main limitation to the therapeutic use of Resveratrol is its low bioavailability (Alcain and Villalba, 2009), so novel formulations are currently included in commercially available nutraceuticals, intended for the treatment and prevention of cardio-metabolic disorders (Timmers et al., 2011). In particular, the administration of commercially available nutraceuticals was associated with an improvement of flow-mediated vasodilation, a surrogate measure of endothelial function, in humans (Fujitaka et al., 2011; Wong et al., 2011).

Similar mechanisms, and similar effects on ED and cardiovascular risk, have been proposed also for other flavonoids, such as Quercetin and Fisetin, although fewer studies have been performed with these agents (Gupta et al., 2018; Patel et al., 2018). Similar to Resveratrol, these compounds are frequently included in commercially available nutraceuticals with claimed anti-oxidant properties.

More recently, non-flavonoid small molecules, able to activate SIRT1 were identified and proposed as potential treatments for humans. These compounds can stimulate SIRT1 activity in vitro of with a hundred-fold higher potency than Resveratrol (Villalba and Alcain, 2012). In vitro and in vivo experiments with SRT1720, a small molecule activator of SIRT1, demonstrated its efficacy in improving mitochondrial biogenesis (Funk et al., 2010), promoting antioxidants expression and blunting inflammation through normalization of NF-kB (Gano et al., 2014). Evidence of the efficacy of this compound in preventing or reducing ED is still limited (Gano et al., 2014; Fiorentino et al., 2015) and no trial in humans has been performed so far. More recently, Scisciola et al. identified two novel potent inhibitors of SIRT1, SCIC2 and its derivative SCIC2.1, which were demonstrated to reduce the progression of cellular senescence in vitro (Scisciola et al., 2020). As reported by Charles et al. the actual efficacy of SRT1 activators is still debatable, due to limitations of the models and validation of the outcomes (Charles et al., 2017).
FUTURE PERSPECTIVES FOR BASIC AND TRANSLATIONAL RESEARCH

Although the role of SIRT1 in aging, and especially in cardiovascular aging, has been extensively studied in the last years, our revision of the literature discloses that still some relevant issues need to be clarified.

From a strictly molecular point of view, the role of SIRT1 in telomeres shortening and nuclear stability, through the interaction with the telomerase complex and lamin A/C, are still poorly understood and need further studies. Similarly, the role of SIRT1 in proteostasis needs to be further investigated. Indeed, the role of SIRT1 and mTOR in autophagy is still largely unclear, whereas a potential role of SIRT1 on the ubiquitin-proteasome system has not been investigated so far.

From a translational point of view, ASCVD seems to associate to a reduction of SIRT1 in tissues, and a paradoxical increase in plasma. This aspect needs to be clarified in details, disclosing the molecular mechanisms underneath. Similarly, the role of SIRT1 gene polymorphisms in cardiovascular risk should be better characterized, in order to investigate whether they are associated with a quantitative or qualitative modification of the protein.

Finally, high-quality clinical trials are necessary to test the effects of PA on SIRT1 and the efficacy of small molecule activators of SIRT1 in reducing cardiovascular risk.

CONCLUSIONS

Sirtuins regulate multiple effector targets involved in multiple cell functions such as mitochondrial respiration, redox balance, apoptosis, cell signaling, and inflammation. All these properties contribute to determine the well-known effect of SIRT1 in preventing cell senescence and prolonging lifespan in animals.

Since the cardiovascular system is severely affected by aging, and ASCVD are the most common age-related diseases in industrialized countries, the pathophysiological role of SIRT1 in ASCVD was intensively investigated in the past 20 years. The results of these studies clearly depict a protective role of SIRT1 toward endothelial integrity and function mainly mediated by the increased bio-availability of NO.

Accordingly, the possibility to enhance the activity of SIRT1 through pharmacologic and non-pharmacologic interventions is a promising perspective in the prevention and treatment of ED and ASVCD, although convincing evidence in humans, and particularly in patients, is still missing. Clinical and pre-clinical studies on this promising topic are still ongoing. Accumulating evidence supports the potential role of CR and PA as non-pharmacologic interventions, whereas flavonoids are currently included in nutraceutical products. Pre-clinical studies with small molecule activators of SIRT1 are showing promising data.

AUTHOR CONTRIBUTIONS

SM, YP, and LL wrote the initial draft of the manuscript. GB created the pictures. FM and GC contributed to revision and manuscript finalization. All authors contributed to manuscript revision, read, and approved the submitted version.

FUNDING

The present work was supported by the Swiss National Science Foundation to GC [310030_197510], and the Foundation for Cardiovascular Research–Zurich Heart House. GC was the recipient of a Sheikh Khalifa’s Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich.

REFERENCES

Abiri, B., and Vafa, M. (2019). Dietary restriction, cardiovascular aging and age-related cardiovascular diseases: a review of the evidence. Adv. Exp. Med. Biol. 1178, 113–127. doi: 10.1007/978-3-030-25650-0_7
Ahmed, M. S., Ikram, S., Bibi, N., and Mir, A. (2018). Hutchinson-Gilford progeria syndrome: a premature aging disease. Mol. Neurobiol. 55, 4417–4427. doi: 10.1007/s12053-017-0610-7
Alcain, F. J., and Villalba, J. M. (2009). Sirtuin activators. Exp. Opin. Ther. Pat. 19, 403–414. doi: 10.1517/13543770902762893
Alcendor, R. R., Gao, S., Zhai, P., Zablocki, D., Holle, E., Yu, X., et al. (2007). Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100, 1512–1521. doi: 10.1161/01.RES.0000267723.65696.4a
Allard, D., Figg, N., Bennett, M. R., and Littlewood, T. D. (2008). Akt regulates the survival of vascular smooth muscle cells via inhibition of FoxO3a and GSK3. J. Biol. Chem. 283, 19739–19747. doi: 10.1074/jbc.M710098200
Alves-Fernandes, D. K., and Jasiulionis, M. G. (2019). The role of SIRT1 on DNA metabolism oxidative stress and sirt1 activity in wistar rats. Biochem. Biophys. Res. Commun. 393, 66–72. doi: 10.1016/j.bbrc.2010.01.080
Arunchalam, G., Yao, H., Sundar, I. K., Caiot, S., and Rahman, I. (2010). SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun. 393, 66–72. doi: 10.1016/j.bbrc.2010.01.080
Bacchetti, T., Ferretti, G., Carbone, F., Ministrini, S., Montecucco, F., Jamialahmadi, T., et al. (2020). Dysfunctional high-density lipoprotein: the role of myeloperoxidase and paraoxonase-1. Curr. Med. Chem. 28, 2842–2850. doi: 10.2174/0929867516666160620095103
Bai, X., Yao, L., Ma, X., and Xu, X. (2018). Small molecules as SIRT modulators. Mini Rev. Med. Chem. 18, 1151–1157. doi: 10.2174/1389557516666160620095103
Berkowitz, D. E., White, R., Li, D., Minhas, K. M., Cernaetich, A., Kim, S., et al. (2003). Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation 108, 2000–2006. doi: 10.1161/01.CIR.0000092948.04444.C7
Bonetti, P. O., Pumper, G. M., Higano, S. T., Holmes, D. R., Kuvim, J. T., and Lerman, A. (2004). Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol. 44, 2137–2141. doi: 10.1016/j.jacc.2004.08.062
Braudy, N., Guillemin, G. J., Mansour, H., Chan-Ling, T., Poljak, A., and Grant, R. (2011). Age related changes in NAD+ metabolism oxidative stress and sirt1 activity in wistar rats. PLoS ONE 6:e19194. doi: 10.1371/journal.pone.0019194
Breitenstein, A., Wyss, C. A., Spescha, R. D., Franzcek, F. C., Hof, D., Riawanto, M., et al. (2013). Peripheral blood monocyte Sirt1 expression is reduced in patients with coronary artery disease. PLoS ONE 8:e53106. doi: 10.1371/journal.pone.0053106
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Joo, P., Hu, L. S., et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96, 857–868. doi: 10.1016/S0092-8674(00)80595-4

Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., et al. (2004). Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011–2015. doi: 10.1126/science.1094637

Caito, S., Rajendraozzat, S., Cook, S., Chung, S., Yao, H., Friedman, A. E., et al. (2010). SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress. FASEB J. 24, 3145–3159. doi: 10.1096/fj.09-151308

Camici, G. G., Savarese, G., Akhmedov, A., and Lüscher, T. F. (2015). Molecular mechanism of endothelial and vascular aging: Implications for cardiovascular disease. Euro. Heart J. 36, 3392–3403. doi: 10.1093/eurheartj/ehv587

Cantó, C., and Auwerx, J. (2009). Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab. 20, 325–331. doi: 10.1016/j.tem.2009.03.008

Carbone, F., and Montecucco, F. (2015). Inflammation in arterial diseases. IUBMB Life 67, 18–28. doi: 10.1002/iub.1344

Cayo, A., Segovia, R., Venturini, W., Moore-Carrasco, R., Valenzuela, C., and Brown, N. (2021). miTOR activity and autophagy in senescent cells, a complex partnership. Int. J. Mol. Sci. 22:1849. doi: 10.3390/ijms2218491

Charles, S., Raj, V., Arkojaraj, J., and Mala, K. (2017). Cavelool1/protein arginine methyltransferas/sirtuin1 as a potential target against endothelial dysfunction. Pharmaco1. Res. 119, 1–11. doi: 10.1016/j.phrs.2017.01.022

Chen, C., Zhou, M., Ge, Y., and Wang, X. (2020). SIRT1 and aging related signaling pathways. Mech. Ageing Dev. 187:111215. doi: 10.1016/j.mad.2020.111215

Chen, C.-A., Wang, T.-Y., Varadharaj, S., Reyes, L. A., Hemann, C., Talukder, M. A. et al. (2010). S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 468, 1115–1118. doi: 10.1038/nature09599

Chen, D., Steele, A. D., Lindquist, S., and Guarente, L. (2005). Increase of mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333, 593–601. doi: 10.1124/jpet.109.161992

Gano, L. B., Donato, A. J., Pasha, H. M., Heurn, C. M., Sindler, A. L., and Seals, D. R. (2014). The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice. Am J Physiol. 307, H1754–H1763. doi: 10.1152/ajpheart.00377.2014

Godö, S., and Shimokawa, H. (2017). Endothelial Functions. Arterioscler. Thromb. Vasc. Biol. 37, e108–e114. doi: 10.1161/ATVBAHA.117.30913

Grabowska, W., Sikora, E., and Bielak-Zmijewska, A. (2017). Sirtuins, a promising target in slowing down the ageing process. Biogerontology 18, 447–467. doi: 10.1007/s10522-017-9765-9

Guarente, L. (2011). Sirtuins, aging, and metabolism. Cold Spring Harb. Symp. Quant. Biol. 76, 81–90. doi: 10.1101/sq1.2011.76.010629

Guarente, L. (2013). Calorie restriction and sirtuins revisited. Genes Dev. 27, 2072–2085. doi: 10.1101/gad.227439.113

Gupta, S. C., Kunnunakkara, A. B., Aggarwal, S., and Aggarwal, B. B. (2018). Inflammation, a double-edge sword for cancer and other age-related diseases. Front. Immunol. 9:2160. doi: 10.3389/fimmu.2018.02160

Haigis, M. C., and Guarente, L. P. (2006). Mammalian sirtuins - emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20, 2913–2921. doi: 10.1101/gad.1467306

Heiss, E. H., and Dirsch, V. M. (2014). Regulation of eNOS enzymatic activity by posttranslational modification. Curr. Pharm. Des. 20, 3503–3513. doi: 10.2174/1381612811319666074

Hernandez-Segovia, A., Nehme, J., and Demaria, M. (2018). Hallmarks of cellular senescence. Trends Cell Biol. 28, 436–453. doi: 10.1016/j.tcb.2018.02.001

Hori, Y. S., Kuno, A., Hosoda, R., and Horio, Y. (2013). Regulation of FOXOs and p53 by SIRT1 modulators under oxidative stress. PLoS ONE 8:e73875. doi: 10.1371/journal.pone.0073875

Houtkooper, R. H., Pirinen, E., and Auwerx, J. (2012). Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell Biol. 13, 225–38. doi: 10.1038/nrm3293

Hsu, Y.-J., Hsu, S.-C., Hsu, C.-P., Chen, Y.-H., Chang, Y.-L., Sadoshima, J., et al. (2013). Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 16, 185–192. doi: 10.1089/rej.2013.05018

Donato, A. J., Magiero, K. A., Lawson, B. R., Durrant, J. R., Lesniewski, L. A., and Seals, D. R. (2011). SIRT1 and vascular endothelial dysfunction with aging in mice and humans. J. Physiol. 589, 4545–4554. doi: 10.1113/jphysiol.2011.212119

Doniacciu, M., Urbanek, K., Nebbioso, A., Sodano, L., Gallo, L., Altucci, L., et al. (2019). Cardioproteective effect of a moderate and prolonged exercise training involves sirtuin pathway. Life Sci. 222, 140–147. doi: 10.1016/j.lfs.2019.03.001

Ferrara, N., Rinaldi, B., Corbi, G., Conti, V., Stiuso, P., Boccuti, S., et al. (2008). Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 11, 139–150. doi: 10.1089/rej.2007.0576

Fiorentino, T. V., Procopio, T., Mancuso, E., Arcidiacono, G. P., Andreozzi, F., Arturi, F., et al. (2015). SIRT1720 counteracts glucosamine-induced endoplasmic reticulum stress and endothelial dysfunction. Cardiovasc. Res. 107, 295–306. doi: 10.1093/ctr/ctv149

Fleming, L., and Busse, R. (2003). Molecular processes involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1–12. doi: 10.1152/ajpregu.00323.2002

Fürstermann, U., and Sessa, W. C. (2012). Nitric oxide synthases: regulation and function. Eur. Heart J. 33, 829–837. doi: 10.1093/eurheartj/ehs304

Fujitaka, K., Otani, H., Jo, F., Ho, J., Nomura, E., Iwasaki, M., et al. (2011). Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutri. Res. 31, 842–847. doi: 10.1016/j.nutres.2011.09.028

Funk, J. A., Odejimi, S., and Schnellmann, R. G. (2010). SIRT1720 induces mitochondrial biogenesis and rescues mitochondrial function after oxidant injury in renal proximal tubule cells. J. Pharmacol. Exp. Ther. 333, 593–601. doi: 10.1124/jpet.109.161992

Ministrini et al. 2021 | V12 | Article 733696

Froniter in Physiology | www.frontiersin.org 8 October 2021 | Volume 12 | Article 733696
associated with atrial fibrillation. Scand. Cardiovasc. J. 55, 213–219. doi: 10.1080/14017431.2021.1889653
Kaspar, J. W., Niture, S. K., and Jaiswal, A. K. (2009). Nrf2/NF-κB (Keap1) signaling in oxidative stress. Free Radiac. Biolog. Med. 47, 1304–1309. doi: 10.1016/j.freeradbiomed.2009.07.035
Kapunminen, A., Suuronen, T., Ojala, J., Kaarniranta, K., and Salminen, A. (2013). Antagonistic crosstalk between NF-kB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell. Signal. 25, 1939–1948. doi: 10.1016/j.cellsig.2013.06.007
Kawai, Y., Garduño, L., Theodore, M., Yang, J., and Arinze, I. J. (2011). Acetylation-promotes the vascular smooth muscle cell re-differentiation through Resveratrol. Biochim. Biophys. Acta Mol. Cell. Res. 1866, 1272–1281. doi: 10.1016/j.bbamcr.2019.04.006
Maiesse, K. (2021). Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1. Neurol. Regen. Res. 16, 448–455. doi: 10.4103/1673-5374.291382
Ministrini, S., and Sadoshima, J. (2015). The role of sirtuins in cardiac disease. Am. J. Physiol. Heart Circ. Physiol. 309, H1375–1389. doi: 10.1152/ajpheart.00532.2015
Mittag, T., Kim, C.-S., Yamashiro, A., Yamamoto, T., Hoffman, T. A., Jung, S.-R., et al. (2007). SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 104, 14855–14860. doi: 10.1073/pnas.0704329104
Michan, S., and Sinclair, D. (2007). Sirtuins in mammals: insights into their biological function. Biochem. J. 404, 1–13. doi: 10.1042/BJ20071040
Ming, G.-F., Wu, K., Hu, K., Chen, Y., and Xiao, J. (2016). NAPRT regulates senescence, proliferation, and migration of endothelial progenitor cells through the SIRT1 ASlncRNA/miR-22/SIRT1 pathway. Biochim. Biophys. Res. Commun. 478, 1382–1388. doi: 10.1016/j.bbrc.2016.08.133
Ministrini, S., Carbone, F., and Montecucco, F. (2021). Updating concepts on atherosclerotic inflammation: from pathophysiology to treatment. Eur. J. Clin. Invest. 51, e13467. doi: 10.1111/eci.13467
Morgan, M. J., and Liu, Z. (2011). Crossstalk of reactive oxygen species and NFκB signaling. Cell. Res. 21, 103–115. doi: 10.1038/cr.2010.178
Mostoslavsky, R., Chua, K. F., Lombard, D. B., Pang, W. W., Fischer, M. R., Gellon, L., et al. (2006). Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 124, 315–329. doi: 10.1016/j.cell.2005.11.044
Myers, J., Kokkins, P., and Nelyin, E. (2019). Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients 11:1652. doi: 10.3390/nutrients11071652
Najafipour, H., Rostamzadeh, F., Yeganeh-Hajahmadi, M., and Joukar, S. (2021). Improvement of cardiac function in rats with myocardial infarction by low-intensity to moderate-intensity endurance exercise is associated with normalization of klotho and SIRT1. J. Cardiovasc. Pharmacol. 77, 79–86. doi: 10.1097/FJC.0000000000000935
Nasiri, M., Rauf, M., Kamfirooie, Z., Zibaeezehad, M. J., and Jamali, Z. (2018). SIRT1 gene polymorphisms associated with decreased risk of atherosclerotic coronary artery disease. Gene 672, 16–20. doi: 10.1016/j.gene.2018.05.117
Ota, H., Akishita, M., Iijima, K., Kaneki, M., and Ouchi, Y. (2007). Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Biol. Cardiol. 43, 571–579. doi: 10.1016/j.yjmbecc.2007.08.008
Ota, H., Eto, M., Kano, M. R., Ogawa, S., Iijima, K., Akishita, M., et al. (2008). Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28, 1634–1639. doi: 10.1161/ATVBAHA.108.164368
Pacifici, F., Di Cola, D., Pastore, D., Abete, P., Guadagni, F., Donadel, G., et al. (2019). Proposed tandem effect of physical activity and siirtuin 1 and 3 activity in regulating glucose homeostasis. Int. J. Mol. Sci. 20:4748. doi: 10.3390/ijms20194748
Palacios, J. A., Herranz, D., Benón, M. L., Velasco, S., Serrano, M., and Blasco, M. A. (2010). SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 191, 1299–1313. doi: 10.1083/jcb.201005160
Panth, N., Paudel, K. R., and Parajuli, K. (2016). Reactive oxygen species: a key hallmark of cardiovascular disease. Adv. Med. 2016:9152732. doi: 10.1155/2016/9152732
Park, S.-J., Ahmad, F., Philp, A., Baar, K., Williams, T., Luo, H., et al. (2012). Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting AMPK phosphodiesterases. Cell 148, 421–433. doi: 10.1016/j.cell.2012.01.017
Patel, R. V., Mistry, B. M., Shinde, S. K., Syed, R., Singh, V., and Shin, H.-S. (2018). Therapeutic potential of quercetin as a cardiovascular agent. Eur. J. Med. Chem. 155, 889–904. doi: 10.1016/j.ejmech.2018.06.053
Peng, S. L. (2008). Foxo in the immune system. Oncogene 27, 2337–2344. doi: 10.1038/onc.2008.26

Ministrini et al. October 2021 | Volume 12 | Article 733696
Piper, M. D. W., and Bartke, A. (2008). Diet and aging. Cell Metab. 8, 99–104. doi: 10.1016/j.cmet.2008.06.012
Prola, A., Pires Da Silva, J., Guilbert, A., Lecru, L., Piqueurre, J., Ribeiro, M., et al. (2017). SIRT1 protects the heart from ER stress-induced cell death through eIF2α deacetylation. Cell Death Differ. 24, 343–356. doi: 10.1038/cdd.2016.138
Puppitasari, Y. M., Lena, S., and Giovanni, G. C. (2021). Role of lifespan-regulating genes in age-related cardiovascular disease. Cardiovasc. Med. 2021:0. doi: 10.4414/CVM.2021.w10055
Rajendran, P., Alzahrani, A. M., Hanieh, H. N., Kumar, S. A., Ben Ammar, R., Rengarajan, T., et al. (2019). Autophagy and senescence: a new insight in selected human diseases. J. Cell. Physiol. 234, 21485–21492. doi: 10.1002/jcp.28895
Rogina, B., and Helfand, S. L. (2004). Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U.S.A. 101, 15998–16003. doi: 10.1073/pnas.0401481101
Sahbekar, A., Serban, C., Ursuona, S., Wong, N. D., Muntner, P., Graham, J. M., et al. (2015). Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors — results from a systematic review and meta-analysis of randomized controlled trials. Int. J. Cardiol. 189, 47–55. doi: 10.1016/j.ijcard.2015.04.008
Sciscoli, L., Sarno, F., Carafa, V., Cosonati, S., Di Maro, S., Ciuffreda, L., et al. (2020). Two novel SIRT1 activators, SC1C2 and SCIC2.1 enhance SIRT1-mediated effects in stress response and senescence. Epigenetics 15, 664–83. doi: 10.1038/s41592-019-07043-9
Shimizu, K. (2011). Cardiac vascular protection afforded by caloric restriction: essential role of nicotinamide synthase. Geriatr. Gerontol. Int. 11, 143–156. doi: 10.1111/j.1447-0594.2010.00675.x
Singh, C. K., Chhabra, G., Ndiaye, M. A., Garcia-Peterson, L. M., MacKenzie, M. D. W., and Bartke, A. (2008). Diet and aging. Cell Metab. 8, 99–104. doi: 10.1016/j.cmet.2008.06.012
Sung, J. Y., Lee, K. Y., Kim, J.-R., and Choi, H. C. (2018). Interaction between SIRT1 and Endothelial Dysfunction. Cell Metab. 2, 305–316. doi: 10.1016/j.cmet.2018.01.009
Stein, S., Lohmann, C., Schäfer, N., Hofmann, J., Rohrer, L., Besler, C., et al. (2010). SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. J. Lipid. Res. 51, 1385–1394. doi: 10.1194/jlr.M110004834
Sun, X., Bu, P., Liu, J., Wang, X., Wu, X., and Zhao, L. (2012). Expression of SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Geriatr. Gerontol. Int. 11, 143–156. doi: 10.1111/j.1447-0594.2010.00675.x
Tissenbaum, H. A., and Guarente, L. (2001). Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410, 227–230. doi: 10.1038/35065638
Tran, H., Brunet, A., Grenier, J. M., Datta, S. R., Fornace, A. J., DiStefano, P. S., et al. (2002). DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296, 530–534. doi: 10.1126/science.1068712
Trinei, M., Migliaccio, E., Bernardi, P., Paolucci, F., Pellici, P., and Giorgio, M. (2013). P66Shc, mitochondria, and the generation of reactive oxygen species. Metab. Enzyme. 528, 99–110. doi: 10.1065/metabol.2013.07.006-9
Villalba, J. M., and Alcain, F. I. (2012). Sirtuin activators and inhibitors. BioFactors Of Exp. 38, 349–359. doi: 10.1002/biof.1032
Viswanathan, M., Kim, S. K., Berdichevsky, A., and Guarente, L. (2005). A role for SIR-2.1 regulation of ER stress response genes in determining C. elegans lifespan. Dev. Cell. 9, 605–615. doi: 10.1016/j.devcel.2005.09.017
Wang, C., Wen, J., Zhou, Y., Li, L., Cui, X., Wang, J., et al. (2015). Apelin induces vascular smooth muscle cells migration via a PI3K/Akt/FoxO3a/MMP-2 pathway. Int. J. Biochem. Cell Biol. 69, 173–182. doi: 10.1016/j.biocel.2015.10.015
Wang, L., Quan, N., Sun, W., Chen, X., Cates, C., Rousseau, T., et al. (2018). Cardiomyocyte-specific deletion of Sirt1 gene sensitizes myocardium to ischaemia and reperfusion injury. Cardiovase. Res. 114, 805–821. doi: 10.1093/cvr/cvy033
Winник, S., Auwerx, J., Sinclair, D. A., and Matter, C. M. (2015). Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. Euro. Heart J. 36, 3404–3412. doi: 10.1093/eurheartj/ehv290
Wong, R. H. X., Howe, P. R. C., Buckley, J. D., Coates, A. M., Kunz, L., and Berry, N. M. (2011). Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 21, 851–856. doi: 10.1016/j.numecd.2010.03.003
Wu, G., Fang, Y.-Z., Yang, S., Lupton, J. R., and Turner, N. D. (2004). Glutathione metabolism and its implications for health. J. Nutr. 134, 489–492. doi: 10.1093/jn/134.3.489
Xia, J., Wu, X., Yang, Y., Zhao, Y., Fang, M., Xie, W., et al. (2012). SIRT1 deacetylates RXF5 and antagonizes repression of collagen type I (COL1A2) transcription in smooth muscle cells. Biochem. Biophys. Res. Commun. 428, 264–270. doi: 10.1016/j.jbc.2012.10.043
Xia, N., Daiber, A., Förstermann, U., and Li, H. (2017). Antioxidant effects of resveratrol in the cardiovascular system. Br. J. Pharmacol. 174, 1633–1646. doi: 10.1111/bph.13492
Xia, N., Strand, S., Schlufert, F., Siuda, D., Reifenberg, G., Kleinten, H., et al. (2013). Role of SIRT1 and FOXO factors in eNOS transcriptional activation by resveratrol. Nitric Oxide Biol. Chem. 32:29–35. doi: 10.1016/j.niox.2013.04.001
Xu, Q., Hao, X., Yang, Q., and Si, L. (2009). Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem. Biophys. Res. Commun. 388, 389–394. doi: 10.1016/j.jbc.2009.08.022
Yamamoto, T., Delirco, J., Naya, A., Hoffman, T. A., Mattagajasingh, L., Kasuno, K., et al. (2009). SIRT1 deacetylates APE1 and regulates cellular base excision repair. Nucleic Acids Res. 38, 832–845. doi: 10.1093/nar/gkp1039
Yamamoto, H., Schoonjans, K., and Auwerx, J. (2007). Sirtuin functions in health and disease. Mol. Endocrinol. 21, 1745–55. doi: 10.1210/me.2007-0079
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., et al. (2004). Modulation of NF-κB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23, 2369–2380. doi: 10.1038/sj.emboj.7600244
Yoshida, H., and Kisugi, R. (2010). Mechanisms of LDL oxidation. Clin. Chim. Acta. 413, 1857–1862. doi: 10.1016/j.cjca.2010.08.038
Zanetti, M., Gortan Cappellari, G., Burekovic, I., Barazzoni, R., Stebel, M., and Ministrini SIRT1 and Endothelial Dysfunction.
function in hypercholesterolemic rabbits. *Int. J. Mol. Med.* 11, 317–320. doi: 10.3892/ijmm.11.3.317

**Conflict of Interest:** GC is coinventor on the International Patent WO/2020/226993 filed in April 2020. The patent relates to the use of antibodies which specifically bind IL-1α to reduce various sequelae of ischemia-reperfusion injury to the central nervous system. GC is a consultant to Sovida solutions limited.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Ministrini, Puspitasari, Beer, Liberale, Montecucco and Camici. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.